Haleon Short Sellers Retreat as Stock Drops 14% in a Week

Haleon plc reports third-quarter results on November 6 in a notably different market environment than it faced at its last print: the stock has fallen 14% over the past week to $8.76, while short interest has continued to drop sharply and borrow conditions remain loose.

The short positioning story has shifted materially since the October 27 preview. Shorts fell another 26% over the past week to roughly 17.9 million shares, extending a retreat that began in late October after a peak near 24 million. That week-on-week decline is one of the largest on record for the name. Borrow costs remain negligible at 0.52%, and availability has expanded further to 968%, meaning there are nearly ten shares available to lend for every one currently borrowed. The lending market is signalling no bearish conviction behind the recent price drop.

Options traders are similarly unmoved by the stock's decline. The put/call ratio of 0.031 is almost exactly in line with its 20-day average of 0.031, sitting flat on a z-score basis. At that level it remains near the bottom of its 52-week range, with the high having reached 0.54 earlier in the year. Call flow continues to dominate, which is inconsistent with the kind of defensive hedging typically seen when a stock falls this sharply in the week before a print. The price action looks more like forced selling or index-related flows than a conviction-driven move against the earnings outcome.

On the ownership register, Pfizer is the standout name. The company filed a Schedule 13D on Haleon, making it an activist on the SEC register, though its most recent amendment in March 2025 no longer lists a current percentage of class, down from a previous 7.3% stake. Per ORTEX's disclosure, 13D/G positions are event-driven filings around the 5% threshold, and holders dropping below that level may not file again. BlackRock has moved in the other direction, lifting its stake to 8.5% per its most recent 13G amendment filed in July 2026, up from 7.3% previously.

The factor score picture adds one further tension. Haleon's analyst recommendation differential ranks in the 92nd percentile of its universe, meaning the Street skew toward buy ratings is unusually strong. Yet the EPS surprise rank sits at just the 17th percentile, and EPS momentum over 30 days ranks at 38. The Thursday print will test whether the bullish analyst consensus is grounded in numbers the company can actually deliver, or whether the sharp price drop this week was the market already marking that gap down.